Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Dynamics and durability of HIV-1 neutralization are determined by viral replication
Nature Medicine, Volume 29, No. 11, Year 2023
Notification
URL copied to clipboard!
Description
Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from HIV-1 neutralizers—persons with HIV-1 who naturally develop broad and potent nAbs—can inform about the dynamics and durability of nAb responses in humans, knowledge which is crucial for the design of future HIV-1 vaccine regimens. To address this, we assessed HIV-1-neutralizing immunoglobulin G (IgG) from 2,354 persons with HIV-1 on or off antiretroviral therapy (ART). Infection with non-clade B viruses, CD4+ T cell counts <200 µl−1, being off ART and a longer time off ART were independent predictors of a more potent and broad neutralization. In longitudinal analyses, we found nAb half-lives of 9.3 and 16.9 years in individuals with no- or low-level viremia, respectively, and 4.0 years in persons who newly initiated ART. Finally, in a potent HIV-1 neutralizer, we identified lower fractions of serum nAbs and of nAb-encoding memory B cells after ART initiation, suggesting that a decreasing neutralizing serum activity after antigen withdrawal is due to lower levels of nAbs. These results collectively show that HIV-1-neutralizing responses can persist for several years, even at low antigen levels, suggesting that an HIV-1 vaccine may elicit a durable nAb response. © 2023, The Author(s).
Authors & Co-Authors
Stecher, Melanie
Germany, Koln
Universität zu Köln
Germany, Koln
Partner Site Bonn-cologne
Dingens, Adam S.
United States, Seattle
Fred Hutchinson Cancer Center
Heger, Eva
Germany, Koln
Universität zu Köln
Knops, Elena
Germany, Koln
Universität zu Köln
Wyen, Christoph
Germany, Koln
Universität zu Köln
Germany, Koln
Praxis am Ebertplatz
Wolf, Timo
Germany, Frankfurt am Main
Goethe-universität Frankfurt am Main
Stephan, Christoph J.
Germany, Frankfurt am Main
Goethe-universität Frankfurt am Main
Suárez, Isabelle
Germany, Koln
Universität zu Köln
Germany, Koln
Partner Site Bonn-cologne
Raju, Nagarajan
United States, Nashville
Vanderbilt University Medical Center
Esser, Stefan
Germany, Duisburg
Universität Duisburg-essen
Streeck, Hendrik
Germany, Koln
Partner Site Bonn-cologne
Germany, Bonn
Universität Bonn
Duerr, Ralf
United States, New York
Nyu Grossman School of Medicine
Nanfack, Aubin Joseph
Cameroon, Yaounde
Medical Diagnostic Center
Cameroon, Yaounde
Chantal Biya International Reference Centre for Research on Hiv/aids Prevention and Management Circb
Zolla Pazner, Susan B.
United States, New York
Icahn School of Medicine at Mount Sinai
Geldmacher, Christof
Germany, Munich
Ludwig-maximilians-universität München
Germany, Munich
Partner Site Munich
Germany, Frankfurt am Main
Fraunhofer Institute for Translational Medicine and Pharmacology Itmp
Geisenberger, Otto
Germany, Munich
Ludwig-maximilians-universität München
Germany, Munich
Partner Site Munich
Kroidl, Arne L.
Germany, Munich
Ludwig-maximilians-universität München
Germany, Munich
Partner Site Munich
William, Wiston
Tanzania, Tanga
National Institute for Medical Research Tanga
Maganga, Lucas Henze
Tanzania, Tanga
National Institute for Medical Research Tanga
Ntinginya, Nyanda Elias
Tanzania, Tanga
National Institute for Medical Research Tanga
Georgiev, Ivelin S.
United States, Nashville
Vanderbilt University Medical Center
United States, Nashville
Vanderbilt University
Vehreschild, Jörg Janne
Germany, Koln
Universität zu Köln
Germany, Koln
Partner Site Bonn-cologne
Höelscher, Michael
Germany, Munich
Ludwig-maximilians-universität München
Germany, Munich
Partner Site Munich
Germany, Frankfurt am Main
Fraunhofer Institute for Translational Medicine and Pharmacology Itmp
Germany, Oberschleissheim
Helmholtz Center Munich German Research Center for Environmental Health
Fätkenheuer, Gerd
Germany, Koln
Universität zu Köln
Germany, Koln
Partner Site Bonn-cologne
Bloom, Jesse D.
United States, Seattle
Fred Hutchinson Cancer Center
United States, Chevy Chase
Howard Hughes Medical Institute
Seaman, Michael S.
United States, Boston
Beth Israel Deaconess Medical Center
Lehmann, Clara
Germany, Koln
Universität zu Köln
Germany, Koln
Partner Site Bonn-cologne
Pfeifer, Nico
Germany, Tubingen
Eberhard Karls Universität Tübingen
Georgiou, George R.
United States, Austin
The University of Texas at Austin
Klein, Florian
Germany, Koln
Universität zu Köln
Germany, Koln
Partner Site Bonn-cologne
Statistics
Authors: 30
Affiliations: 23
Identifiers
Doi:
10.1038/s41591-023-02582-3
ISSN:
10788956
Research Areas
Infectious Diseases
Study Design
Cohort Study